Usefulness of Hyperemic Microvascular Resistance Index as a Predictor of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction

Xiongjie Jin, MD, Myeong-Ho Yoon, MD, Kyoung-Woo Seo, MD, Seung-Jea Tahk, MD, Hong-Seok Lim, MD, Hyoung-Mo Yang, MD, Byoung-Joo Choi, MD, So-Yeon Choi, MD, Gyo-Seung Hwang, MD, Joon-Han Shin, MD, and Jin-Sun Park, MD

Department of Cardiology, Ajou University School of Medicine, Suwon, Korea

Background and Objectives: Microvascular function is a useful predictor of left ventricular functional changes in patients with ST-segment elevation myocardial infarction (STEMI). We evaluated the usefulness of the hyperemic microvascular resistance index (hMVRI) for predicting long-term major adverse cardiovascular events (MACEs) in patients with STEMI assessed immediately after primary percutaneous coronary intervention (PCI).

Subjects and Methods: hMVRI were evaluated in 145 patients with first acute STEMI treated with primary PCI using an intracoronary Doppler wire. hMVRI was defined as the ratio of mean aortic pressure over hyperemic averaged peak velocity of infarct-related artery. Major adverse cardiovascular events (MACEs) included cardiac death and re-hospitalization for congestive heart failure.

Results: During the mean follow-up of 85±43 months, MACEs occurred in 17.2% of patients. Using a receiver-operating characteristics analysis, hMVRI >2.82 mm Hg·cm⁻¹·sec⁻¹ (sensitivity: 87%; specificity: 69%; and area under curve: 0.818) was the best cut-off values for predicting future cardiac events. The Cox proportional hazard analysis showed that hMVRI was an independent predictor for long-term MACEs (hazard ratio 1.741, 95% confidence interval 1.348-2.264, p<0.001). The Kaplan-Meier survival analysis showed a higher incidence of MACEs in patients with hMVRI >2.82 mm Hg·cm⁻¹·sec⁻¹ (p<0.001).

Conclusion: hMVRI was a strong predictor of long-term MACEs in patients with STEMI treated with primary PCI.

(KEY WORDS: Myocardial infarction; Microcirculation; Percutaneous coronary intervention.)

Introduction

Minimizing myocardial infarct size and preserving the left ventricle are a major determinant of clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention (PCI) is widely accepted as the most effective reperfusion modality for STEMI, and invasive evaluation of the indices of microvascular function measured after PCI are useful predictors of any left ventricular functional changes, remodeling, and clinical outcomes. Therefore, measuring the microvascular function of infarct-related myocardial territory at the catheterization laboratory may allow for early identification of patients with high risk and determine the treatment strategy and monitoring. Several indices such as the index of microvascular resistance (IMR), hyperemic microvascular resistance index (hMVRI), coronary flow reserve (CFR), coronary wedge pressure, and phasic coronary flow patterns have been studied for evaluating microvascular integrity in patients with STEMI. Previous studies...
have shown that the IMR and hMVRI measured during optimal hyperemia are not affected by coronary hemodynamic statuses such as heart rate, preload, and afterload.\(^{5(0)}\)

Thus, these indices have good reproducibility compared to CFR or another indice.\(^{1(1)}\) However, the effect of hMVRI on long-term clinical outcomes in patients with STEMI has not been evaluated.

We evaluated the usefulness of hMVRI measured immediately after primary PCI in patients with STEMI during a long-term follow-up.

**Subjects and Methods**

**Study population**

We retrospectively enrolled 145 patients who underwent primary PCI within 24 hours after onset of symptoms, and hMVRI was evaluated immediately after revascularization between January 1999 and March 2008. The diagnosis of STEMI was based on characteristic chest pain >30 minutes duration, significant ST segment elevation (>1 mm at limb lead and >2 mm at precordial lead) in ≥ two contiguous electrocardiography leads, and an elevation of the myocardial band of creatine phosphokinase ≥ three times the upper normal limit. Exclusion criteria were previous myocardial infarction, the presence of cardiacogenic shock, a history of PCI or coronary artery bypass graft, left main coronary artery disease, the presence of moderate to severe valvular lesions, and any significant arrhythmia or refractory ventricular arrhythmia rendering an intracoronary Doppler study inappropriate. In addition, patients with post-procedural thrombolysis in myocardial infarction (TIMI) <2 were excluded from the study. The study protocol was approved by the Ajou University Hospital Institutional Review Board.

**Coronary angiographic procedure**

At admission, patients were pretreated with chewable aspirin (300 mg) and clopidogrel (600 mg) as a loading dose or ticlopidine (500 mg) before coronary angiography. All patients received a bolus injection of 5000 IU heparin before angiography, and intravenous infusion of heparin was started (1000 U/hr). Additional heparin was administered to maintain an active clotting time >300 seconds during the procedure. We used the femoral artery approach with a 7 or 8 French guiding catheter for all patients. A stent was implanted following appropriate predilation by balloon catheter. All patients were advised to maintain lifelong aspirin (100 mg/day). Ticlopidine (500 mg/day) or clopidogrel (75 mg/day) was administered for at least 1 month in patients that received bare metal stents or for 1 year in patients that received drug-eluting stents. The quantitative coronary angiographic analysis was performed using the cardiovascular angiography analysis system II (CAAS II, pie Medical, Maastricht, Netherlands). After successful primary PCI, a contrast flow through the infarct-related artery was graded on the standard TIMI flow scale of 0 to 3 from the final coronary angiogram. Use of a thrombectomy device or distal protection device before PCI and the use of glycoprotein IIb/IIIa receptor inhibitor were determined according to the physician’s discretion.

**Microvascular functional assessment**

After primary PCI, 100-300 ug nitroglycerin was administered into the coronary artery, and a 0.014-inch Doppler Flowire (12 MHz, FloWire™, Cardiometrics, Mountain View, CA, USA) was advanced through the guiding catheter. The tip of the wire was placed precisely just distal to the site of the culprit lesion to assess the microvascular function of the entire region at risk. A bolus of 48-60 ug adenosine was used for the left coronary artery and 24-36 ug for the right coronary artery, followed by a 5-10 mL saline flush to induce optimal hyperemia. The CFR was defined as the ratio of the hyperemic averaged peak velocity (hAPV, cm/sec) to baseline averaged peak velocity (bAPV, cm/sec). hMVRI was calculated from the mean aortic pressure at the catheter tip divided by hAPV.\(^{1(3)}\) immediately after successful PCI.

**Assessment of left ventricular function by echocardiography at admission and follow-up**

Evaluation of the left ventricular function was performed with a commercially available echocardiography. The ejection fraction (EF) was measured on apical 4- and 2-chamber views by Simpson’s method. The left ventricle was divided into 16 segments according to the recommendation of the American Society of Echocardiography.\(^{1(3)}\) The global wall motion score index (WMSI) was analyzed and calculated using both endocardial motion and wall thickening and was quantified using a 5-grade scoring system as follows: 1=normal; 2=hypokinesia; 3=akinesia; 4=dyskinesia; and 5=aneurismal changes. The echocardiographic evaluation was performed by a cardiologist who was unaware of the results of the physiologic study.

**Clinical follow-up**

All patients were evaluated at the outpatient clinic and by telephone interviews. The primary endpoint of the study was major adverse cardiac events (MACEs) defined as a composite of cardiac death and re-hospitalization for congestive heart failure (CHF). CHF was defined by the simultaneous presence of at least 2 major criteria or 1 major criteria and 2 minor criteria as reported by the Framingham Heart Study.\(^{1(4)}\)

**Statistical analysis**

The continuous variables were expressed as mean±standard
deviation, and the discrete variables were expressed as counts and percentages. The Student’s t-test was used for the continuous variables, and the chi-square test and the Fisher exact t-test were used for the categorical variables. Pearson’s and Spearman’s correlation coefficients were calculated as appropriate. The Cox regression analysis was performed to analyze the independent impact of MACE at a long-term period. All variables with $p<0.2$ in univariate analysis were entered into a multivariate analysis. The results were presented as a hazard ratio with 95% confidence intervals (CI) and $p$ value. Survival curves with cumulative events were prepared according to the Kaplan–Meier method and compared using the log-rank test. A $p<0.05$ was considered significant.

### Results

#### Baseline clinical, angiographic, and procedural results

Between January 1999 to March 2008, a total of 145 patients were retrospectively enrolled. Table 1 and 2 summarize the clinical, angiographic, and procedural characteristics of patients with and without MACEs. Patients with MACEs were less likely to be male

### Table 1. Clinical characteristics of patients with and without cardiovascular events

|                        | Patients without MACE (n=120) | Patients with MACE (n=25) | $p$   |
|------------------------|-------------------------------|---------------------------|-------|
| Age (years)            | 56±12                         | 57 ± 11                   | 0.461 |
| Male (%)               | 106 (88)                      | 18 (72)                   | 0.035 |
| Hypertension (%)       | 50 (42)                       | 15 (60)                   | 0.094 |
| Diabetes mellitus (%)  | 26 (22)                       | 8 (78)                    | 0.267 |
| Dyslipidemia (%)       | 34 (28)                       | 11 (44)                   | 0.123 |
| Smoking (%)            | 77 (64)                       | 16 (36)                   | 0.987 |
| EF at baseline         | 51±9                          | 43±10                     | <0.001|
| WMSI at baseline       | 1.49±0.28                     | 1.71±0.35                 | 0.001 |
| Laboratory measurements|                              |                           |       |
| Total Cholesterol (mg/dL) | 184±42                       | 211±48                    | 0.006 |
| Triglyceride           | 142±118                       | 188±143                   | 0.101 |
| HDL-Cholesterol        | 43±10                         | 45±9                      | 0.398 |
| LDL-Cholesterol        | 112±39                        | 115±36                    | 0.757 |
| Peak CK (U/L)          | 3202±2304                     | 4190±2579                 | 0.062 |
| Peak CK-MB (ug/mL)     | 297±172                       | 356±203                   | 0.138 |
| Medication at discharge|                              |                           |       |
| ACE inhibitor/ARB (%)  | 105 (88)                      | 19 (76)                   | 0.137 |
| Beta-blocker (%)       | 89 (74)                       | 16 (26)                   | 0.301 |
| Calcium channel blocker| 62 (52)                       | 13 (64)                   | 0.976 |
| Aspirin (%)            | 120 (100)                     | 50 (100)                  | 1.00  |
| Clopidogrel/ticlopidine (%) | 117 (98)                  | 23 (92)                   | 0.170 |
| Statins (%)            | 78 (65)                       | 15 (60)                   | 0.635 |
| Hemodynamics           |                              |                           |       |
| Blood pressure, mean   | 81.02±15.03                   | 85.27±15.04               | 0.427 |
| Heart rate, mean       | 77.53±17.67                   | 84.95±21.08               | 0.122 |
| CFR                    | 1.93±0.69                     | 1.51±0.57                 | 0.006 |
| bAPV (cm/sec)          | 20.80±8.67                    | 16.11±5.63                | 0.011 |
| hAPV (cm/sec)          | 37.53±16.30                   | 23.96±9.03                | <0.001|
| hMVRI                  | 2.65±1.12                     | 4.37±1.54                 | <0.001|

MACE: major adverse cardiovascular event, EF: ejection fraction, WMSI: wall motion score index, HDL: high density lipoprotein, LDL: low density lipoprotein, CK: creatine kinase, CK-MB: creatine kinase-myocardial band, ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, CFR: coronary flow velocity reserve, bAPV: baseline average peak velocity, hAPV: hyperemic average peak velocity, hMVRI: hyperemic microvascular resistance index
(88% vs. 72%, p=0.035), had lower EF (43±10 vs. 51±9, p<0.001) and higher WMSI (1.71±0.35 vs. 1.49±0.28, p=0.001) at baseline, a decreased CFR (1.51±0.57 vs. 1.93±0.69, p=0.006) and an increased hMVRI (4.37±1.54 vs. 2.65±1.12, p<0.001) compared to the patients without MACEs (Fig. 1). In addition, patients with MACEs achieved less often a post-procedural TIMI 3 flow.

Clinical outcome and impact of hMVRI on cardiovascular events

The mean follow-up duration was 85±43 months. Total MACEs occurred in 25 (17.2%) patients. Cardiac death occurred in 11 patients, and CHF requiring hospital admission occurred in 14 patients. The results of a receiver operating characteristic curve analysis for the prediction of MACE are shown in Fig. 2. The best cut-off value for hMVRI to predict MACEs during long-term follow-up was 2.82 mm Hg·cm⁻¹·sec (area under the curve: 0.818, p=0.006), thus providing a sensitivity of 87% and specificity of 69%. A Cox proportional hazard analysis identified hMVRI (hazard

---

**Table 2.** Angiographic and procedural characteristics of patients with and without cardiovascular events

|                                | Patients without MACE (n=120) | Patients with MACE (n=25) | p     |
|--------------------------------|--------------------------------|---------------------------|-------|
| Infarct-related artery, n (%)  |                                |                           | 0.285 |
| LAD                           | 80 (67)                        | 16 (64)                   |       |
| LCX                           | 5 (4)                          | 3 (12)                    |       |
| RCA                           | 35 (29)                        | 6 (24)                    |       |
| Multi-vessel disease, n (%)   | 38 (35)                        | 11 (44)                   | 0.375 |
| Use of thrombectomy device, n %| 33 (30)                        | 5 (20)                    | 0.316 |
| Use of stent, n (%)           |                                |                           | 0.818 |
| DES                            | 51 (43)                        | 10 (40)                   |       |
| BMS                            | 69 (57)                        | 15 (60)                   |       |
| RVD (mm)                      | 3.44±0.35                      | 3.42±0.36                 | 0.806 |
| Pre-PCI                        |                                |                           |       |
| MLD (mm)                      | 0.27±0.46                      | 0.27±0.51                 | 0.948 |
| DS (%)                        | 92.2±13.9                      | 92.0±15.2                 | 0.892 |
| Post-PCI                       |                                |                           |       |
| MLD (mm)                      | 3.20±0.34                      | 3.10±0.37                 | 0.122 |
| DS (%)                        | 6.91±5.27                      | 9.38±5.47                 | 0.009 |
| Coronary flow at baseline, n (%)|                                |                           | 0.206 |
| TIMI <3                       | 98 (82)                        | 23 (92)                   |       |
| TIMI 3                        | 22 (18)                        | 2 (8)                     |       |
| Coronary flow at procedure end, n (%)|                    |                           | <0.001|
| TIMI <3                       | 11 (9)                         | 9 (36)                    |       |
| TIMI 3                        | 109 (91)                       | 16 (64)                   |       |

MACE: major adverse cardiovascular event, LAD: left anterior descending artery, LCX: left circumflex artery, RCA: right coronary artery, DES: drug-eluting artery, BMS: bare metal stent, RVD: reference vessel diameter, PCI: percutaneous coronary intervention, MLD: minimal lumen diameter, DS: diameter stenosis, TIMI: thrombolysis in myocardial infarction

![Fig. 1.](http://dx.doi.org/10.4070/kcj.2015.45.3.194)
Table 3. The Cox hazards analysis for predictors of cardiovascular events

|                  | Univariate          | Multivariate        |
|------------------|---------------------|---------------------|
|                  | HR (95% CI)         | p                   | HR (95% CI)         | p                   |
| hMVRI            | 1.619 (1.090-2.403) | 0.017               | 1.747 (1.348-2.264) | <0.001              |
| CFR              | 0.603 (0.261-1.390) | 0.235               |                     |                     |
| bAPV             | 0.998 (0.941-1.058) | 0.945               |                     |                     |
| hAPV             | 0.983 (0.934-1.034) | 0.496               |                     |                     |
| EF (%)           | 0.909 (0.862-0.958) | <0.001              | 0.910 (0.862-0.961) | 0.001               |
| WMSI             | 5.228 (1.410-19.385)| 0.013               |                     |                     |
| Age              | 1.056 (1.016-1.097) | 0.006               |                     |                     |
| Diabetes         | 1.540 (0.677-3.507) | 0.303               |                     |                     |
| Hypertension     | 1.419 (0.633-3.182) | 0.396               |                     |                     |
| Dyslipidemia     | 1.220 (0.549-2.715) | 0.626               |                     |                     |
| Smoking          | 1.232 (0.541-2.802) | 0.619               |                     |                     |
| Peak CK          | 1.000 (1.000-1.000) | 0.635               |                     |                     |
| Peak CK-MB       | 1.001 (0.998-1.003) | 0.701               |                     |                     |
| Post-PCI         |                     |                     |                     |                     |
| TIMI 3 flow      | 0.610 (0.257-1.447) | 0.262               |                     |                     |

HR: hazard ratio, CI: confidence interval, hMVRI: hyperemic microvascular resistance index, CFR: coronary flow velocity reserve, bAPV: baseline average peak velocity, hAPV: hyperemic average peak velocity, EF: ejection fraction, WMSI: wall motion score index, CK: creatine kinase, CK-MB: creatine kinase-myocardial band, PCI: percutaneous coronary intervention, TIMI: thrombolysis in myocardial infarction.

As a subgroup analysis, patients were divided into two groups: patients with hMVRI ≤2.82 mm Hg·cm⁻¹·sec (n=87) and patients with hMVRI >2.82 mm Hg·cm⁻¹·sec (n=58). Clinical, angiographic, and procedural characteristics are listed in Table 4. Patients with hMVRI >2.82 mm Hg·cm⁻¹·sec were more likely to have a history of hypertension as well as lower EF (46±8 vs. 52±10, p<0.001) and higher WMSI (1.64±0.29 vs. 1.45±0.29, p<0.001) at baseline, a decreased CFR (1.57±0.62 vs. 2.04±0.67, p<0.001) compared with
the patients with hMVRI ≤2.82 mm Hg-cm⁻¹-sec. A final TIMI grade 3 flow was less frequently achieved in patients with hMVRI >2.82 mm Hg-cm⁻¹-sec (Table 4). Multivariable analysis showed that the independent determinants for hMVRI >2.82 mm Hg-cm⁻¹-sec were CFR (odds ratio [OR] 0.475, 95% CI 0.239–0.945; p=0.034), EF (OR 0.939, 95% CI 0.892–0.990, p=0.019), and final TIMI flow 3 (OR 0.035, 95% CI 0.004–0.290, p=0.002) (Table 5).

Discussion
This present study showed that for patients with STEMI, favorable long-term outcomes occurred in patients with lower hMVRI
as compared with in patients with higher hMVRI, and the microvascular indices were measured by an intracoronary Doppler wire immediately after primary PCI. The MACES were significantly more frequent in patients with high hMVRI for long-term follow-up. The present study herein demonstrated for the first time that the hMVRI was an independent predictor of total MACE at a long-term period. Therefore, early measurement of microvascular function after primary PCI may be helpful in determining the early therapeutic strategy and monitoring. A microvascular dysfunction in the territory of a revascularized artery was related with the inability of a previously ischemic region to be reperfused, and a microvascular integrity was associated with any left ventricular functional changes and clinical outcomes in patients with acute myocardial infarction (AMI). Thus, identifying the status of microvascular integrity in individual patients was crucial for establishing a treatment strategy. The microvascular indices measured by a intracoronary Doppler guidewire or intracoronary pressure wire offered a better quantitative assessment of the microvascular status of the myocardium in patients with AMI compared to angiographic flow indices and had good correlations with the severity of myocardial damage, changes in the left ventricular function, or clinical outcomes of AMI. However, the microvascular integrity indices measured immediately after reperfusion might be favorably or adversely affected by many confounding factors. First, the microvascular functional status did not recover completely in the early stages of AMI. Second, these indices may be affected by many hemodynamic factors such as the baseline coronary blood flow, heart rate, and collateral functions independent of any microvascular and myocardial damage. Third, it was not uncommon that distal thromboembolization to microvasculature, epicardial and microvascular spasm, and cellular edema could affect the microvascular integrity at the early stage of AMI. Therefore, the microvascular function and coronary flow in the infarct territory may be altered with time, particularly in the early stage of AMI after primary PCI. Therefore, an accurate evaluation of infarct size and severity by microvascular integrity indices was difficult in the early stages of STEMI, particularly immediately after reperfusion therapy. Previous studies have suggested that CFR measured by intracoronary Doppler wire was correlated with changes in the left ventricular function and the clinical outcome.

However, the coefficient of variation of CFR may be up to 20% because CFR was largely affected by the baseline coronary flow velocity associated with heart rate, preload, contractility, and after PCI whereas the hyperemic coronary flow velocity was not affected by these hemodynamic conditions. An IMR suggested recently by Fearon et al. was associated with much lower variability and was not significantly affected by changes in the hemodynamic conditions in contrast to CFR because the hyperemic coronary flow velocity-used variables of this index were not related to the heart rate and preload as compared to CFR. A recent study demonstrated that hMVRI estimated using a novel dual-sensor (pressure and Doppler velocity) guidewire immediately after primary PCI was correlated with infarct size as defined by cardiac magnetic resonance, and increased microvascular resistance index was related to higher transmural extent of the infarction grade; also, this index was more accurate than CFR for predicting transmural MI. However, research about the association between hMVRI and clinical outcomes and the usefulness of hMVRI for predicting clinical outcomes in patients with STEMI has not been studied. In the present study, hMVRI measured by Doppler wire immediately after primary PCI in patients with STEMI was higher in patients with cardiovascular events compared to that of patients without cardiovascular events. The current results provide a possible explanation for the strong association between the microvascular dysfunction and any future development of cardiac death and CHF during long-term follow-ups. Our results suggest that for increased hMVRI measured immediately after PCI in patients with STEMI, long-term aggressive medical management was warranted to prevent MACE during the long-term follow-up.

Our study had several limitations. First, it was a retrospective, single center, long-term study. Therefore, different treatment regimens and strategies for STEMI in early-stage and late-stage patients such as medications and kinds of stents and different follow-up durations occurred. Thus, some bias cannot be excluded for the effect of these confounding factors on the clinical outcomes independent of the microvascular integrity. However, we found that the hMVRI remained a strong independent predictor of cardiovascular events for up to 12 years. Second, we measured hMVRI as a ratio of mean aortic pressure at the coronary catheter tip and distal hAPV. However, we measured hMVRI after successfully removing epicardial stenosis by successful PCI. If there had been any significant stenosis in the epicardial stenosis, hMVRI may be related primarily to epicardial stenosis. Because a minimum of residual stenosis due to successful PCI occurred, the effect of minimal epicardial stenosis as a predictor of hMVRI was effectively excluded. Third, we evaluated the microvascular function in patients with stable vital signs during primary PCI and in only patients that achieved TIMI grade ≥2 after PCI. Thus, the importance of post-PCI TIMI score as a predictor of future cardiac events decreased compared to that in previous studies.

In conclusion, hMVRI was a strong predictor of the development of long-term MACES in patients with STEMI treated with primary PCI.
References

1. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-30.
2. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002;105:1909-13.
3. Fearon WF, Balsam LB, Farouque HM, et al. Novel index for invasively assessing the coronary microcirculation. Circulation 2003;107:3129-32.
4. Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2008;51:560-5.
5. Lim HS, Yoon MH, Tahk SJ, et al. Usefulness of the index of microcirculatory resistance for invasively assessing myocardial viability immediately after primary angioplasty for anterior myocardial infarction. Eur Heart J 2009;30:2854-60.
6. Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial reperfusion by intravenous myocardial contrast echocardiography and coronary flow reserve after primary percutaneous transluminal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction. Circulation 2000;101:2368-74.
7. Takahashi T, Hiasa Y, Ohara Y, et al. Usefulness of coronary flow reserve immediately after primary coronary stenting in predicting wall motion recovery in patients with anterior wall acute myocardial infarction. Am J Cardiol 2004;94:1033-7.
8. Yoon MH, Tahk SJ, Yang HM, et al. Comparison of accuracy in the prediction of left ventricular wall motion changes between invasively assessed microvascular integrity indexes and fluorine-18 fluorodeoxyglucose positron emission tomography in patients with ST-elevation myocardial infarction. Am J Cardiol 2008;102:129-34.
9. Yamamoto K, Ito H, Iwakura K, et al. Pressure-derived collateral flow index as a parameter of microvascular dysfunction in acute myocardial infarction. J Am Coll Cardiol 2001;38:1383-9.
10. Kawamoto T, Yoshida K, Akasaka T, et al. Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angioplasty [correction of angiography] predict recovery of regional left ventricular function in patients with acute myocardial infarction? Circulation 1999;100:339-45.
11. Ng MK, Yeung AC, Fearon WF. Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation 2006;113:2054-61.
12. Klauss V, Ackermann K, Henneke KH, et al. Epicardial intimal thickening in transplant coronary artery disease and resistance vessel response to adenosine: a combined intravascular ultrasound and Doppler study. Circulation 1997;96(Suppl 9): II-159-64.
13. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
14. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6.
15. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-40.
16. Furber AP, Prunier F, Nguyen HC, Boulet S, Delépine S, Geslin P. Coronary blood flow assessment after successful angioplasty for acute myocardial infarction predicts the risk of long-term cardiac events. Circulation 2004;110:3527-33.
17. Leung DY, Leung M. Non-invasive/invasive imaging: significance and assessment of coronary microvascular dysfunction. Heart 2011;97:587-95.
18. van Liebergen RA, Piek JJ, Koch KT, de Winter RJ, Lie Kl. Immediate and long-term effect of balloon angioplasty or stent implantation on the absolute and relative coronary blood flow velocity reserve. Circulation 1998;98:2133-40.
19. Kitabata H, Imanishi T, Kubo T, et al. Coronary microvascular resistance index immediately after primary percutaneous coronary intervention as a predictor of the transmural extent of infarction in patients with ST-segment elevation anterior acute myocardial infarction. JACC Cardiovasc Imaging 2009;2:263-72.
20. Anjeja BG, Gibson CM. Preserved coronary flow reserve in viable myocardium: further evidence for the microvascular hypothesis. Am Heart J 2001;141:329-30.
21. Aarnoudse W, Fearon WF, Manoharan G, et al. Epicardial stenosis severity does not affect minimal microcirculatory resistance. Circulation 2004;110:2137-42.